

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this notice, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this notice.



Shanghai HeartCare Medical Technology Corporation Limited

上海心璋醫療科技股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 6609)

NOTICE OF THE EXTRAORDINARY GENERAL MEETING

NOTICE IS HEREBY GIVEN that the extraordinary general meeting (the “**EGM**”) of Shanghai HeartCare Medical Technology Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) will be held at HeartCare Hall, 2/F, Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC on Wednesday, November 8, 2023 at 10:00 a.m. for the purpose of considering, and if thought fit, passing the following resolutions. Unless otherwise defined, capitalized terms used in this notice shall have the same meanings as those defined in the circular of the Company dated October 20, 2023 (the “**Circular**”).

SPECIAL RESOLUTION

1. To consider and approve the proposed extension of the validity period of the Resolutions concerning the A Share Issue and the Authorization concerning the A Share Issue.

ORDINARY RESOLUTIONS

2. To consider and approve the re-election and appointment of Mr. WANG Guohui as the Executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.
3. To consider and approve the re-election and appointment of Ms. ZHANG Kun as the Executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and she shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.

4. To consider and approve the re-election and appointment of Mr. WEI Jiawei as the Executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive remuneration in accordance with the relevant policies and the unified standards set by the Company.
5. To consider and approve the re-election and appointment of Mr. DING Kui as the Non-executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall not be entitled to receive any remuneration for his position as a Non-executive Director.
6. To consider and approve the re-election and appointment of Mr. CHEN Shaoxiong as the Non-executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall be entitled to a fixed remuneration of RMB120,000 per year (before tax).
7. To consider and approve the election and appointment of Mr. CHEN Gang as the Non-executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall not be entitled to receive any remuneration for his position as a Non-executive Director.
8. To consider and approve the re-election and appointment of Mr. GUO Shaomu as the Independent Non-executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of HKD260,000 per year (before tax).
9. To consider and approve the re-election and appointment of Mr. FENG Xiangqian as the Independent Non-executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of HKD220,000 per year (before tax).
10. To consider and approve the re-election and appointment of Mr. GONG Ping as the Independent Non-executive Director of the Company for a term of three (3) years commencing from the date of approval at the EGM, and he shall receive a fixed remuneration of RMB200,000 per year (before tax).
11. To consider and approve the re-election and appointment of Mr. JIANG Xinbei as the Supervisor of the Company for a term of three (3) years commencing from the date of approval at the EGM and he shall not be entitled to receive any remuneration for his position as a Supervisor.

12. To consider and approve the re-election and appointment of Ms. JIANG Xue as the Supervisor of the Company for a term of three (3) years commencing from the date of approval at the EGM and she shall not be entitled to receive any remuneration for her position as a Supervisor.

By Order of the Board
Shanghai HeartCare Medical Technology Corporation Limited
WANG Guohui
Chairman of the Board

Shanghai, October 20, 2023

Notes:

1. Any Shareholder of the Company entitled to attend and vote at the EGM is entitled to appoint one or more proxies to attend and, on a poll, vote instead of him/her. A proxy need not be a member of the Company.
2. The instrument appointing a proxy shall be in writing under the hand of the appointer or of his/her attorney duly authorized in writing or, if the appointer is a corporation, either under its seal or under the hand of any officer or attorney duly authorized.
3. In order to be valid, the form of proxy together with the power of attorney or other authority, if any, under which it is signed or a notarially certified copy of such power or authority, must be deposited with Computershare Hong Kong Investor Services Limited at 17M Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong (for holders of H Shares) or the Company's registered office at Floor 1 and 3, Building 38, No. 356, Zhengbo Road, Lingang New District, Pilot Free Trade Zone, Shanghai, PRC (for holders of Unlisted Shares) as soon as practicable but in any event not less than 24 hours before the time appointed for holding the EGM (i.e., at or before 10:00 a.m. on Tuesday, November 7, 2023 (Hong Kong Time)), or any adjourned meeting thereof (as the case may be).
4. Completion and return of the form of proxy shall not preclude the Shareholders of the Company from attending and voting in person at the EGM or at any adjourned meeting thereof (as the case may be) should they so wish, and in such event, the form of proxy shall be deemed to be revoked.
5. Where there are joint registered holders of any share, any one of such joint holders may vote, either in person or by proxy, in respect of such share as if he/she was solely entitled thereto, but if more than one of such joint holders are present at the EGM, whether in person or by proxy, the joint registered holder present whose name stands first on the register of members of the Company in respect of the shares shall alone be entitled to vote in respect thereof.
6. For the purpose of determining the Shareholders of the Company entitled to attend and vote at the EGM, the register of members of the Company has been closed from Monday, October 9, 2023 to Wednesday, November 8, 2023 (both days inclusive). The record date for determining the entitlement of the Shareholders of the Company to attend and vote at the EGM will be Wednesday, November 8, 2023. In order to qualify for the entitlement to attend and vote at the above EGM, H Shareholders must lodge all transfer forms accompanied by the relevant H Share certificates with the Company's H Share registrar in Hong Kong, Computershare Hong Kong Investor Services Limited, at Shops 1712-1716, 17th Floor, Hopewell Centre, 183 Queen's Road East, Wan Chai, Hong Kong by no later than 4:30 p.m. on Friday, October 6, 2023.

7. The EGM is expected to take less than half a day. Shareholders who attend the EGM shall be responsible for their own travel and accommodation expenses. Shareholders may contact the Investor Relations Department of the Company at +86 21 5897 5056 or info@heartcare.com.cn for any enquiries in respect of the EGM.

As at the date of this notice, the executive Directors are Mr. Wang Guohui, Ms. Zhang Kun and Mr. Wei Jiawei; the non-executive Directors are Mr. Ding Kui and Mr. Chen Shaoxiong; and the independent non-executive Directors are Mr. Guo Shaomu, Mr. Feng Xiangqian and Mr. Gong Ping.